Evista, Raloxifene Newswire

Evista, Raloxifene Newswire

Comprehensive Real-Time News Feed for Evista, Raloxifene (generic).

Results 1 - 20 of 21 in Evista, Raloxifene (generic)

  1. Postmenopausal Osteoporosis Therapeutics Market- Leveraging Demand by 2021Read the original story w/Photo

    May 9, 2018 | SBWire

    Osteoporosis is an orthopedic condition where the bone density and bone mass decreases and eventually increases the risk of bone fracture. Osteoporosis is one of the most common age related diseases worldwide and also represents a major public health problem.

    Comment?

  2. Predictive values of diagnostic codes for identifying serious...Read the original story w/Photo

    Apr 9, 2018 | BioMed Central

    Post-marketing safety studies of medicines often rely on administrative claims databases to identify adverse outcomes following drug exposure. Valid ascertainment of outcomes is essential for accurate results.

    Comment?

  3. 4 Breast Cancer Studies Pharmacists Should Know AboutRead the original story w/Photo

    Mar 4, 2018 | Pharmacy Times

    Breast cancer is a disease in which there is uncontrolled growth of breast cells. It's estimated that approximately 1 in 8 U.S. women will develop invasive breast cancer over the course of her lifetime and just under 40,000 women will die from the disease in 2018.

    Comment?

  4. Drug Repurposing Market- Latest Trends and Future Growth Study by 2025Read the original story w/Photo

    Mar 28, 2018 | SBWire

    Drug repurposing or re-profiling has been the hallmark to bring strong business growth and the trend is being followed by majority of the pharmaceutical and biopharmaceutical companies. Among all biologics approved in the U.S. during 2007-2009, 30-40% of them were the drugs repurposed or repositioned.

    Comment?

  5. Drug Repurposing Market to Be at Forefront by 2025Read the original story w/Photo

    Feb 22, 2018 | SBWire

    Drug repurposing or re-profiling has been the hallmark to bring strong business growth and the trend is being followed by majority of the pharmaceutical and biopharmaceutical companies. Among all biologics approved in the U.S. during 2007-2009, 30-40% of them were the drugs repurposed or repositioned.

    Comment?

  6. Anti-Osteoporosis Therapy and Fracture Healing Market Current...Read the original story w/Photo

    Feb 16, 2018 | SBWire

    Osteoporosis is a chronic and a life-threatening disease in which the microstructure of bones is altered due to reduction in bone mass and bone density. This condition leads to increased bone brittleness and risk of bone fractures and cracks.

    Comment?

  7. Anti Osteoporosis Therapy and Fracture Healing Market: Future Market...Read the original story w/Photo

    Jan 24, 2018 | SBWire

    Osteoporosis is a chronic and a life-threatening disease in which the microstructure of bones is altered due to reduction in bone mass and bone density. This condition leads to increased bone brittleness and risk of bone fractures and cracks.

    Comment?

  8. Bisphosphonate treatment of osteoporosis.Read the original story

    Nov 21, 2017 | CiteULike

    Bisphosphonates represent the agents of choice for most patients with osteoporosis. They are the best studied of all agents for the prevention of bone loss and reduction in fractures.

    Comment?

  9. A review of teriparatide and its clinical efficacy in the treatment of osteoporosis.Read the original story

    Nov 21, 2017 | CiteULike

    To insert individual citation into a bibliography in a word-processor, select your preferred citation style below and drag-and-drop it into the document. Until recently, antiresorptive medications such as bisphosphonates and raloxifene represented the main pharmacological treatment options for patients with osteoporosis.

    Comment?

  10. Finding the right osteoporosis medicationRead the original story w/Photo

    Oct 17, 2017 | PhysOrg Weblog

    Dear Mayo Clinic: The bisphosphonate drugs I take for osteoporosis aren't working in my case. My doctor has suggested a few alternatives.

    Comment?

  11. V. Craig Jordan, Ph.D., elected to the National Academy of MedicineRead the original story w/Photo

    Oct 16, 2017 | Newswise

    Craig Jordan, Ph.D., professor of Breast Medical Oncology, has been elected to the National Academy of Medicine for his discovery of selective estrogen receptor modulators , a class of drugs with far-reaching impact on women's health. Jordan's findings include application of the original SERM, the estrogen-blocking drug tamoxifen, to the treatment and prevention of breast cancer, and discovery that raloxifene prevents both osteoporosis and breast cancer.

    Comment?

  12. The effect of alendronate, risedronate, and raloxifene on renal...Read the original story

    Oct 11, 2017 | CiteULike

    The effect of alendronate, risedronate, and raloxifene on renal functions, based on the Cockcroft and Gault method, in postmenopausal women. Oral alendronate, risedronate, and raloxifene are effective treatment options in the management of postmenopausal osteoporosis.

    Comment?

  13. Confusion about long-term treatment of osteoporosis clarifiedRead the original story w/Photo

    Oct 11, 2017 | PhysOrg Weblog

    Osteoporosis is a common disorder among postmenopausal women which results in an increased risk of fractures. While several therapies improve bone strength and reduce the risk of spine and hip fracture, there is no cure for osteoporosis, and long-term treatment is needed.

    Comment?

  14. Systematic review of the use of bone turnover markers for monitoring...Read the original story

    Oct 6, 2017 | CiteULike

    Systematic review of the use of bone turnover markers for monitoring the response to osteoporosis treatment: the secondary prevention of fractures, and primary prevention of fractures in high-risk groups. There is currently no standard practice for the monitoring of patients receiving treatment for osteoporosis.

    Comment?

  15. Drug Repurposing Market to Witness Decline in Demand by 2017 - 2025Read the original story w/Photo

    Sep 8, 2017 | SBWire

    Drug repurposing or re-profiling has been the hallmark to bring strong business growth and the trend is being followed by majority of the pharmaceutical and biopharmaceutical companies. Among all biologics approved in the U.S. during 2007-2009, 30-40% of them were the drugs repurposed or repositioned.

    Comment?

  16. Raloxifene Hydrochloride Industry Forecast 2023Read the original story w/Photo

    Sep 6, 2017 | SBWire

    Raloxifene hydrochloride is an oral medication intended for the prevention of osteoporosis in postmenopausal women. In addition, raloxifene hydrochloride medications are also used for the reduction of risk and treatment of invasive breast cancer.

    Comment?

  17. Osteoporosis needs treatmentRead the original story w/Photo

    Aug 7, 2017 | Weirton Daily Times

    DEAR DR. ROACH: I'm a 61-year-old female, and my recent DEXA bone density scan resulted in measurements of -2.7 in the lumbar region and -2.1 in both femoral necks.

    Comment?

  18. Learn Details of the Global Anti-Osteoporosis Therapy and Fracture Healing Market 2025Read the original story w/Photo

    Jul 25, 2017 | SBWire

    Osteoporosis is a chronic and a life-threatening disease in which the microstructure of bones is altered due to reduction in bone mass and bone density. This condition leads to increased bone brittleness and risk of bone fractures and cracks.

    Comment?

  19. An Endocrinologist Explains Her View Of Tymlos And The Osteoporosis LandscapeRead the original story w/Photo

    Jul 21, 2017 | Seeking Alpha

    Amgen's osteoporosis drug for postmenopausal women was rejected 7/16/2017. Competitor Radius' injectable drug, abaloparatide-SC, targets the same patient group and received approval 4/28/17.

    Comment?

  20. Press release distribution, EDGAR filing, XBRL, regulatory filingsRead the original story w/Photo

    Jul 20, 2017 | Business Wire

    The dividend will be payable Septe... )--The "Migraine Disease Coverage Forecast and Market Analysis" report has been added to Research and Markets' offering. Migraine is a common, disabling, and recurring neurolo... Seasonal Influenza Vaccines KOL Interviews 2017 - Vaccines discussed are Fluad, FluBlok, Flucelvax, FluMist Quadrivalent , Fluzone High Dose and Intanza .

    Comment?